Patents by Inventor Xuan BEATTY

Xuan BEATTY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20190359980
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: April 12, 2019
    Publication date: November 28, 2019
    Inventors: David RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY
  • Oligonucleotide compositions and uses thereof
    Patent number: 10316318
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: June 11, 2019
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: David Rodman, Anita Seto, Christina Dalby, Aimee Jackson, Xuan Beatty
  • OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20190106695
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: May 10, 2018
    Publication date: April 11, 2019
    Inventors: David RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY
  • Oligonucleotide compositions and uses thereof
    Patent number: 9994852
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 12, 2018
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: David Rodman, Anita Seto, Christina Dalby, Aimee Jackson, Xuan Beatty
  • MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
    Publication number: 20180127750
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: August 15, 2017
    Publication date: May 10, 2018
    Inventors: David RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY
  • OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF
    Publication number: 20180037890
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 8, 2018
    Inventors: David RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY
  • miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
    Patent number: 9771585
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 26, 2017
    Assignee: MIRAGEN THERAPEUTICS, INC.
    Inventors: David Rodman, Anita Seto, Christina Dalby, Aimee Jackson, Xuan Beatty
  • MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL)
    Publication number: 20160355814
    Abstract: The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: June 3, 2016
    Publication date: December 8, 2016
    Inventors: David RODMAN, Anita SETO, Christina DALBY, Aimee JACKSON, Xuan BEATTY